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ABSTRACT   
objectives: To assess the efficacy, tolerability and acceptability of oxycodone for cancer pain in 
adults 
methods: We searched CENTRAL, MEDLINE, MEDLINE In-Process, Embase, SCI, Conference 
Proceedings Citation Index-Science, BIOSIS, PsycINFO, and four trials registries to November 2016. 
results: We included 23 RCTs with 2144 patients analysed for efficacy and 2363 for safety. Meta-
analyses showed no significant differences between controlled-release and immediate-release 
oxycodone in pain intensity or adverse events; but did show significantly better pain relief after 
treatment with controlled-release morphine compared to controlled-release oxycodone. However, 
sensitivity analysis did not corroborate this result. Meta-analyses of the adverse events showed a 
significantly lower risk of hallucinations after treatment with CR oxycodone compared to CR 
morphine, but no other differences. The remaining studies either compared oxycodone in various 
formulations or compared oxycodone to different alternative opioids. None found any clear 
superiority or inferiority of oxycodone in pain relief or adverse events. The quality of this evidence 
base was limited by the high/unclear risk of bias of the studies and the low event rates for many 
outcomes. 
conclusions: Oxycodone offers similar levels of pain relief and adverse events to other strong opioids. 
However, hallucinations occurred less with CR oxycodone than with CR morphine, but the quality of 
this evidence was very low so this finding should be treated with utmost caution. Our conclusions are 
consistent with other reviews and suggest that  oxycodone can be used first-line as an alternative to 





INTRODUCTION   
Pain from cancer can be caused by direct invasion of a tumour into soft tissue or bone and is often a 
presenting symptom at the time of diagnosis of cancer. One European survey published in 2009 found 
that, of 5000 people with cancer (including 617 community-based National Health Service (NHS) 
patients in the UK), 72% experienced pain (77% of UK patients) which was of moderate to severe 
intensity in 90% of this group.[1] This is consistent with a systematic review that demonstrated cancer 
pain prevalence of up to 75% in advanced disease, and that at least 30% of people with cancer are 
undertreated.[2] Recent research has also shown that less than half of all people with cancer that die 
are prescribed a strong opioid, and that median treatment duration is only nine weeks before death.[3] 
Pain in people with cancer may also be caused by cancer treatments and by comorbid conditions. In 
this review, we define cancer pain as pain arising as a direct consequence of the cancer, and not from 
other aetiologies. 
 
Oxycodone is a strong opioid analgesic indicated for the treatment of moderate to severe chronic pain, 
including cancer pain. It is available orally as immediate-release (IR) solution and tablets (for four-
hourly dosing) and as sustained (controlled (CR)) release tablets (for 12-hourly dosing). It is also 
available as a parenteral injection. In some countries, oxycodone is available as a compound with 
paracetamol (acetaminophen) or ibuprofen. 
 
Oxycodone works primarily as an agonist of mu-opioid receptors in the spinal cord and brain. It has 
some activity at kappa-opioid receptors (which are also involved in nociception or analgesia) though 
the importance of this mechanism in the overall analgesic effect of oxycodone is unclear. Despite 
animal studies suggesting differences in pharmacodynamics, these have not been demonstrated in 
clinical studies to date. Therefore, the shared mechanism of action to other strong opioids (i.e. agonist 
activity at mu-opioid receptors) means that clinical benefits and adverse effects are likely to be 
similar. However, important differences exist in the pharmacokinetics of strong opioids (e.g. 
morphine undergoes second-phase elimination via glucuronidation, while oxycodone undergoes 
extensive first-phase metabolism via CYP2D6 and CYP3A4 pathways) so clinical equivalence cannot 
be inferred.[4-5] 
 
The World Health Organization (WHO) published the Method for Cancer Pain Relief (WHO 
analgesic ladder) in 1986,[6] which advocates a stepwise approach to analgesia for cancer pain and 
revolutionised the use of oral opioids. It recommended that morphine be used first line for moderate to 
severe cancer pain. Observational studies have suggested that this approach results in pain control for 
73% of people[7] with a mean reduction in pain intensity of 65%.[8] 
Many people with cancer experience moderate to severe pain that requires treatment with strong 
analgesics. Oxycodone and morphine are examples of strong opioids that are used for the relief of 
cancer pain. However, strong opioids are not effective for pain in all people, neither are they well 
tolerated by all people. Guidance by the European Association for Palliative Care on the use of 
opioids in cancer pain suggests that oxycodone could be used as first-line treatment of moderate to 
severe cancer pain as an alternative to morphine.[9] The aim of this review is to assess whether 
oxycodone is associated with better pain relief (efficacy), tolerability and acceptability than other 
analgesic options for adults with cancer pain.  
 
This review is an updated Cochrane systematic review on oxycodone for cancer-related pain.[10] 
 
METHODS   
We included randomised controlled trials (RCTs), with parallel-group or cross-over design, 
comparing oxycodone (any formulation and any route of administration) with placebo or an active 
drug (including oxycodone) for cancer background pain in aGXOWVDJHG\HDUV. We did not 
examine studies on breakthrough pain. The studies had to report patient-reported pain intensity/relief 
with or without adverse events (e.g. constipation, nausea, vomiting, drowsiness, confusion, respiratory 
depression), quality of life (or treatment acceptability as a proxy), and participant preference. If 
possible, we aimed to distinguish between nociceptive and neuropathic pain, but the data were not 
presented in a manner that made this possible. 
 
We performed a search of electronic databases (November 2016) and trials registers (December 2016) 
and checked the bibliographic references of relevant identified studies to find additional trials not 
identified by the electronic searches and contacted authors of the included studies to ask if they knew 
of any other relevant studies. We applied no language, date, or publication status (published in full, 
published as abstract, unpublished) restrictions to the search or the study inclusion criteria (See the 
method section of the Supplementary File for full search strategy).  
 
Two authors independently assessed the study records identified by the search for potential inclusion, 
extracted data pertaining to study design, participant details (including age, cancer characteristics, 
previous analgesic medication, and setting), interventions (including details about titration), and 
outcomes and assessed the methodological quality of each of the included studies by using the 'Risk 
of bias' assessment method outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions.[11] We resolved any disagreements by discussion.  
 
For pain intensity, we extracted the means and standard deviations (SD) and we used these to estimate 
the standardised mean difference (SMD) between the treatments along with the 95% confidence 
interval (CI), as the outcome was not measured on the same scale across studies. For adverse events, 
we extracted event rates to calculate risk ratios (RR) with 95% CIs as the summary estimates. 
  
The participant was the unit of analysis, but in a number of cases the data reported in the included 
cross-over trials could not otherwise be incorporated into the analyses, so we included them as if the 
design had been parallel-group. This approach gives rise to unit-of-analysis error, but is conservative 
as it results in an underweighting of the data.[11] However, in order to assess the impact of this 
strategy, we also performed sensitivity analyses when we included cross-over trial data in this manner 
by excluding the cross-over trials from the meta-analyses. 
 
We contacted the authors to request missing data. We limited imputation of missing data to the 
imputation of missing SDs, either by calculating the SD if enough information was available or by 
using SDs from similar samples or studies, both according to the methods outlined by Higgins and 
Green.[11] We only imputed SDs for pain intensity for Lux et al[12], which were not reported for the 
subgroup of participants with malignant pain, by using the reported SDs for the whole sample of 
participants with either malignant (n = 31) or non-malignant pain (n = 15), and for Yu et al[13] for the 
primary outcome of the study "mean pain at its worst in the past 24 hours" by using the standard 
deviations for the same outcome measured at baseline in the full analysis set. It was not possible to 
assess the impact of missing data in sensitivity analyses due to the low number of included studies 
within each comparison. In all cases, we aimed to perform intention-to-treat (ITT) analyses. 
 
We assessed heterogeneity by using the I2 statistic, with I2 >50% representing substantial 
heterogeneity,[11] and had enough data been available, we had planned to assess potential sources of 
heterogeneity through subgroup analyses. Similarly, we had planned to examine the robustness of the 
meta-analyses by conducting sensitivity analyses using different components of the 'Risk of bias' 
assessment. Unfortunately, we were unable to perform any such sensitivity analyses due to the low 
number of studies within each comparison. 
 
We meta-analysed the data extracted from the included studies whenever possible (i.e., when the data 
were reported in a manner that allowed it to be included in the meta-analyses) using Review Manager 
5.[14] We analysed pain intensity using the generic inverse variance method using a fixed-effects 
model as the I2 statistic was <50%. We meta-analysed the adverse events data using the Mantel-
Haenszel method using a fixed-effects model in all cases; however, as this method is not suitable for 
cross-over trial data, we only included the data from parallel-group trials in these analyses. We used 
the GRADE system to rank the quality of the evidence using the GRADEprofiler Guideline 
Development Tool software (GRADEpro GDT 2015;[15] see the method section of the 




The search identified a total of 1121 unique records of which 1014 were excluded based on 
title/abstract and the full-texts of 107 records were retrieved. Of these 107 records, 23 studies 
published in 28 articles were included and 64 records were excluded because they were: Not 
examining the population or comparison of interest (36); systematic (11) or narrative reviews (six); 
not RCTs/RCT-based analyses (seven), letters to the editor (two), duplicates (one) or case reports 
(one). In addition to these, there were six studies awaiting classification, and nine ongoing studies 
(See WKHµCharacteristics of ongoing studies¶ and µCharacteristics of studies awaiting classification¶
tables, respectively, in the results section of the Supplementary File). A number of the studies 
identified in the searches compared oxycodone in combination with another drug (e.g. naloxone or 
acetaminophen) against oxycodone alone or placebo. Such studies were not included as they would 
not answer our primary question, which concerned the effectiveness of oxycodone for cancer pain.  
The 23 included studies enrolled/randomised 2648 participants (1347 men, 1109 women; for the 
remaining 192 participants gender was not specified) with 2144 of these analysed for efficacy and 
2363 for safety. The reported mean/median ages of the participant populations in the studies ranged 
from 45 years to 68.8 years. Eleven of the studies were cross-over trials (published in 16 articles),[12, 
16-30] and 12 were parallel-group trials (published in 13 articles),[13, 31-42] with eight of the studies 
conducted in the USA;[16-17, 20-21, 29-30, 33, 35-36, 39] two in Canada;[18, 22] two in 
Finland;[23-25] three in China;[13, 40, 42] three in Italy;[31, 34, 41] and one each in 
Germany/Poland/Switzerland,[12] Australia,[28] Brazil,[27] the UK,[37-38] and Japan/Korea.[32] 
The length of the trials ranged from single-dose treatment to one year, and the studies reported the 
following comparisons: 
x CR oxycodone versus IR oxycodone;[29-30, 33, 36, 39] 
x CR oxycodone versus extended-release (ER) oxycodone;[12] 
x CR oxycodone versus CR morphine,[18-19, 23-24, 27, 31, 34-35, 37-38, 41-42] with one of 
these studies including a further two arms of transdermal (TD) buprenorphine and TD 
fentanyl;[31] and one of the studies comparing two different brands of slow-release morphine 
to CR oxycodone;[42] 
x CR oxycodone versus CR hydromorphone;[22] 
x CR oxycodone versus ER hydromorphone;[13] 
x CR oxycodone versus ER oxymorphone;[20-21] 
x CR oxycodone versus ER tapentadol;[32] 
x CR oxycodone versus TD fentanyl;[31, 40] 
x CR oxycodone versus TD buprenorphine;[31] 
x intravenous (IV) oxycodone versus rectal oxycodone;[28] 
x IV oxycodone followed by IR oxycodone versus IV morphine followed by IR morphine;[25-
26] 
x intramuscular (IM) oxycodone versus oral oxycodone;[16] 
x IM oxycodone versus IM morphine versus IM codeine.[17] 
 
See also Characteristics of included studies in the Supplementary file for further details about the 
studies. 
 
See Figure 1 for summaries of the 'risk of bias' judgements made for the included studies. In the 
majority of the studies not enough information was reported to assess whether the methods employed 
to generate the randomisation sequence and to ensure allocation concealment were adequate. 
Relatedly, it was also unclear whether the participant selection methods employed had resulted in 
comparable, balanced groups at study start in the majority of the studies. The risks of performance 
and detection bias were considered to be low for pain intensity/relief and adverse events in about half 
of the studies, unclear in four studies, and high in six of the studies that were all described as open-
label. Overall the data from only 81% of the total number of enrolled/randomised participants were 
analysed for pain and 89.2% for adverse events, which indicates that attrition bias was a substantial 
problem in this data set. Five studies either did not report adverse events or did not report them in a 
manner so they could be scrutinised for (and potentially included in) an evidence synthesis.[12, 16-19, 
27] One study only reported four adverse events in a transparent manner.[22] The participants 
appeared to be adequately titrated in the majority of the studies,[12-13, 18-27, 29-32, 35-38, 40-42] 
although this was unclear in four studies,[16-17, 28, 34] and not the case in one study.[33] One study 
examined titration as its main objective.[39] For all 11 cross-over trials, data were available for all 
cross-over phases. Only four studies undertook ITT analyses for both efficacy and safety,[28-30, 36, 
42] with a further three studies performing these analyses for safety only[25-26, 39] or for efficacy 
only.[31, 37-38] In one study, it was unclear whether ITT analyses had been undertaken.[40] The 
remaining studies did not perform ITT for any of the outcomes. The vast majority of the included 
studies had received commercial funding or had authors who were employees of the drug 
manufacturers, or both.[12-13, 16-17, 20-24, 28-30, 32-33, 35-36, 39, 41] Only three studies were 
considered free from the potential influence of commercial funding,[25-26, 31, 37-38] with a further 
five studies having unclear status.[18-19, 27, 34, 40, 42]  
 
pain   
Figure 2 shows the pain intensity scores for each of the listed treatment groups, sub-grouped 
according to the treatment comparisons.  
 
Pooled analysis showed that there was no statistically significant difference in pain intensity after 
treatment with either CR or IR oxycodone (SMD 0.1, 95% CI -0.06 to 0.26, I2 = 35%). Sensitivity 
analysis excluding the cross-over trial[29-30] did not change the overall results (SMD 0.12, 95% CI -
0.06 to 0.29). The study by Salzman et al could not be included in the pooled analysis due to the 
design of the study, but found that CR oxycodone could be used as readily as IR oxycodone for 
titration to stable pain control with 22/24 and 19/24 participants in the CR and IR groups, 
respectively, achieving stable pain control within a mean time of 1.6 days (SE = 0.4) and 1.7 days (SE 
= 0.6), respectively.[39] We judged the quality of evidence for this outcome to be low. We 
downgraded the quality of evidence by two levels for very serious limitations to study quality due to 
risk of bias (arising from under-reporting and attrition bias).  
 
Pooled analysis showed that the pain intensity scores were significantly lower after treatment with CR 
morphine than with CR oxycodone (SMD 0.14, 95% CI 0.01 to 0.27, I2 = 7%). Using the SD of the 
baseline average pain score of the full sample (200 participants; SD 1.94) from the study by Riley et 
al[37-38] to express this SMD as a difference in Brief Pain Inventory scores (0 to 10 numerical rating 
scale from no pain to worst pain imaginable) between the treatments gave an estimated difference of 
0.27 between the treatments, which was not clinically significant. Moreover, sensitivity analysis 
excluding the two cross-over trials[18-19, 23-24] did not find a significant difference between CR 
oxycodone and CR morphine (SMD 0.12, 95% CI -0.02 to 0.26, I2 = 24%). Two studies could not be 
included in the pooled analysis due to the design of the study[27] or because pain intensity was not 
reported.[42] Lauretti et al conducted a two-phase (each lasting 14 days) cross-over study to examine 
IR morphine consumption during treatment with CR oxycodone and CR morphine, keeping the ratio 
of CR oxycodone and CR morphine constant (1:1.8).[27] IR morphine was used as rescue medication 
and the participants were allowed to take as much as necessary to keep visual analogue scale pain 
score <4. The participants consumed 38% more IR morphine during treatment with CR morphine than 
with CR oxycodone. Lauretti et al concluded that the results indicated that CR oxycodone combined 
with IR morphine was associated with superior analgesia and lower, or similar, rates of adverse events 
(see 'Adverse events' below) than a combination of CR and IR morphine.[27] Zhang et al conducted a 
three-arm parallel-group trial of unknown duration comparing CR oxycodone to CR morphine and CR 
MS Contin and found that pain relief rates (i.e. participants experiencing at least moderate pain relief) 
of the three groups did not differ significantly (CR oxycodone 53/57 participants; CR morphine 51/57 
participants; CR MS Contin 52/57 participants; P = 0.62).[42] We judged the quality of evidence for 
this outcome to be low. We downgraded the quality of evidence by two levels for very serious 
limitations to study quality due to risk of bias (arising from under-reporting, performance/detection 
bias, and attrition bias).  
 
Pooled analysis showed that the pain intensity scores after treatment with CR oxycodone and TD 
fentanyl did not differ significantly (SMD 0.02, 95% CI -0.19 to 0.24, I2 = 0%). We judged the quality 
of evidence for this outcome to be very low. We downgraded the quality of evidence by two levels for 
very serious limitations to study quality due to risk of bias (arising from under-reporting, performance 
bias, and detection bias), and by one level for imprecision (arising from low participant numbers). 
 
The remaining treatment comparisons (whether included in Figure 2 or not) were only examined by 
one study each and none of them found any statistically significant differences in the pain scores 
between the respective treatments with the exception of Leow et al who in a small single-dose cross-
over study with 12 participants found that while IV oxycodone was associated with faster onset of 
pain relief relative to rectal oxycodone, rectal oxycodone was associated with a longer duration of 
pain relief compared to IV oxycodone.[28] We judged the quality of the evidence for these outcomes 
to be low or very low as we downgraded the quality of the evidence by one or two levels for 
serious/very serious limitations to study quality due to risk of bias (arising from under-reporting, 
performance bias, detection bias and/or attrition bias), and by one or two levels for imprecision 




Table 1 lists the pooled analyses of the adverse events.  
 
Table 1 list the meta-analyses of the adverse events data from the following comparisons: CR 
oxycodone versus IR oxycodone, CR oxycodone versus CR morphine and CR oxycodone versus TD 
fentanyl.   
Outcome and 
subgroup 










Any adverse event  
CR OXY v CR MOR 3 142/196 (72.4) 152/203 (74.9) 0.97 (0.87, 1.09) 53 
Asthenia  
CR OXY v IR OXY 2 5/102 (4.9) 9/106 (8.5) 0.58 (0.2, 1.68) 30 
Confusion  
CR OXY v IR OXY 2 3/78 (3.8) 4/79 (5.1) 0.78 (0.2, 3.02) 25 
CR OXY v CR MOR 3 74/295 (25.1) 73/289 (25.3) 1.01 (0.78, 1.31) 16 
Constipation  
CR OXY v IR OXY 3 25/156 (16) 36/161 (22.4) 0.71 (0.45, 1.13) 38 
CR OXY v CR MOR 5 139/400 (34.8) 141/397 (35.5) 0.98 (0.82, 1.16) 33 
CR OXY v TD FEN 2 88/171 (51.5) 80/165 (48.5) 1.07 (0.88, 1.32) 83 
Dizziness/lightheadedness  
CR OXY v IR OXY 3 15/156 (9.6) 21/161 (13) 0.74 (0.4, 1.37) 15 
CR OXY v CR MOR 3 9/186 (4.8) 12/181 (6.6) 0.76 (0.33, 1.76) 0 
Drowsiness/somnolence  
CR OXY v IR OXY 3 36/156 (23.1) 36/161 (22.4) 1.03 (0.69, 1.54) 0 
CR OXY v CR MOR 5 121/400 (30.3) 134/398 (33.7) 0.9 (0.75, 1.08) 0 
Dry mouth  
CR OXY v IR OXY 3 10/156 (6.4) 9/161 (5.6) 1.14 (0.48, 2.75) 0 
CR OXY v CR MOR 4 89/343 (25.9) 89/341 (26.1) 1.01 (0.8, 1.26) 32 
Dysuria  
CR OXY v CR MOR 2 17/186 (9.1) 24/186 (12.9) 0.71 (0.4, 1.26) 0 
CR OXY v TD FEN 2 19/171 (11.1) 16/165 (9.7) 1.15 (0.62, 2.16) 0 
Hallucinations  
CR OXY v CR MOR 4 14/349 (4) 27/347 (7.8) 0.52 (0.28, 0.97) 0 
Headache  
CR OXY v IR OXY 3 8/156 (5.1) 10/161 (6.2) 0.83 (0.34, 2.02) 61 
Insomnia  
CR OXY v IR OXY 2 5/132 (3.8) 5/137 (3.6) 1.04 (0.31, 3.53) 35 
Nausea  
CR OXY v IR OXY 3 32/156 (20.5) 39/161 (24.2) 0.85 (0.56, 1.28) 0 
CR OXY v CR MOR 5 108/400 (27) 106/398 (26.6) 1.02 (0.82, 1.26) 0 
Nervousness  
CR OXY v IR OXY 2 5/102 (4.9) 9/106 (8.5) 0.57 (0.2, 1.64) 0 
Pruritus  
CR OXY v IR OXY 3 13/156 (8.3) 9/161 (5.6) 1.46 (0.65, 3.25) 33 
CR OXY v CR MOR 4 29/343 (8.5) 36/341 (10.6) 0.81 (0.51, 1.29) 0 
Sweating  
CR OXY v IR OXY 2 5/132 (3.8) 8/137 (5.8) 0.65 (0.22, 1.93) 55 
Vomiting  
CR OXY v IR OXY 3 18/156 (11.5) 28/161 (17.4) 0.66 (0.38, 1.15) 18 
CR OXY v CR MOR 5 60/400 (15) 64/398 (16.1) 0.94 (0.68, 1.29) 2 
Discontinuation due to adverse events  
CR OXY v IR OXY 3 11/156 (7.1) 19/161 (11.8) 0.6 (0.29, 1.22) 0 
CR OXY v CR MOR 3 9/196 (4.6) 9/203 (4.4) 1.06 (0.43, 2.6) 48 
Abbreviations: CR = controlled-release; FEN = fentanyl; IR = immediate-release; MOR = morphine; 
OXY = oxycodone; TD = transdermal   
 
Pooled analyses showed no significant difference between treatment with CR and IR oxycodone for 
any of the adverse events. However, the I2 statistic was 61% for headache and 55% for sweating so 
the results reported in Table 1 for these two adverse events should be disregarded and are instead 
presented in Figures 3 and 4. Parris et al analysed 109 participants for safety evaluation; however, it is 
unclear which group had 55 and which had 54 participants.[36] In the meta-analyses of adverse 
events, we allocated 54 participants to the CR oxycodone group and 55 to the IR oxycodone group. 
Sensitivity analyses showed that allocating 55 participants to the CR oxycodone group and 54 
participants to the IR oxycodone group made no difference to the conclusions. Stambaugh et al in a 
cross-over study stated that: "The study showed similar incidences and numbers of reports of 
individual adverse events considered related to the IR and CR drug" (page 505), but did not report any 
formal statistical comparisons of the adverse event rates between the study groups.[30] We judged the 
quality of evidence for adverse events to be very low for all adverse events. We downgraded the 
quality of evidence by two levels for very serious limitations to study quality due to risk of bias 
(arising from under-reporting, performance/detection bias, inadequate titration, attrition bias, or a 
combination of these); and we downgraded the quality of the evidence by one or two levels due to 
imprecision (arising from low or very low event rates). 
 
Pooled analyses of adverse events showed no significant difference between treatment with CR 
oxycodone and CR morphine for any of the adverse events apart from hallucinations where the risk 
ratio was significantly lower after treatment with CR oxycodone than after CR morphine. Moreover, 
the I2 statistic was 53% for 'any adverse events' so the results reported in Table 1 for this outcome 
should be disregarded and are instead presented in Figure 5. Zhang et al compared CR oxycodone to 
both CR morphine and CR MS Contin.[42] In the meta-analyses of adverse events, we included CR 
morphine as the comparison group. Sensitivity analyses substituting the CR morphine data with the 
CR MS Contin data showed that whether the comparison group was CR morphine or CR MS Contin 
made no difference to the conclusions. 
 
Bruera et al reported that: "There were no statistically significant differences by treatment in mean 
severity for any of the elicited adverse events or in the frequency of reporting of unelicited events" 
(page 3225), but presented only data on sedation and nausea VAS ratings.[18]  Corli et al found no 
significant differences between the two treatment groups in the incidences of gastralgia and 
breathlessness, whether they were 'any degree' or 'severe.' Severe but not 'any degree' muscle spasm 
myoclonus occurred significantly more often in the CR morphine group than in the CR oxycodone 
group.[31] Heiskanen et al in a cross-over trial found that vomiting was significantly more common 
during morphine treatment while constipation was significantly more common during oxycodone 
treatment; and reported no other significant differences in adverse event rates between the drugs.[23-
24] Mercadante et al found no significant differences in the reported adverse events between the 
groups.[34] Lauretti et al found that CR and IR morphine were associated with more nausea and 
vomiting compared to the combination of CR oxycodone and IR morphine.[27] We judged the quality 
of evidence for this outcome to be very low for all adverse events. We downgraded the quality of 
evidence by two levels for very serious limitations to study quality due to risk of bias (arising from 
under-reporting, performance/detection bias, attrition bias, or a combination of these), and we 
downgraded the quality of the evidence by one or two levels due to imprecision (arising from low or 
very low event rates). 
 
Pooled analysis showed that there was no significant difference between CR oxycodone and TD 
fentanyl for dysuria and that the I2 statistic was 83% for constipation. The results reported for 
constipation in Table 1 should therefore be disregarded and considered on a study-by-study basis only 
for this treatment comparison (see also Figure 6). Corli et al found no significant differences between 
the two treatment groups in the incidences of the following adverse events, whether they were 'any 
degree' or 'severe': drowsiness, confusion, nausea, vomiting, constipation, dry mouth, hallucinations, 
gastralgia, muscle spasm myoclonus, breathlessness, and itching.[31] Su et al reported that the rates of 
nausea and vomiting (P = 0.026) and constipation (P = 0.022) were significantly higher in the CR 
oxycodone group than in the TD fentanyl group, and that the rates of dizziness and lethargy did not 
differ significantly between the groups (ps > 0.65).[40] We judged the quality of evidence for this 
outcome to be very low. We downgraded the quality of evidence by two levels for very serious 
limitations to study quality due to risk of bias (arising from under-reporting, performance bias, and 
detection bias), and by one or two levels (depending on the event rates of the individual adverse 
events) for imprecision (arising from low or very low event rates). 
 
A number of the remaining studies did not report adverse events split or inferentially analysed by 
treatment group.[12, 16-17, 20-21, 28, 32] Of those studies that did perform the analyses,[13,22, 25-
26, 31] no significant differences were found between the treatment groups with the following 
exceptions:    
- Drowsiness occurred more frequently during treatment with CR oxycodone compared to CR 
hydromorphone,[22]   
'Any degree,' but not severe, breathlessness occurred more often in the TD buprenorphine group than 
in the CR oxycodone group.[31] 
- Nausea was significantly more common with oral morphine treatment compared to IV oxycodone, 
IR oxycodone and IV morphine.[25-26] 
We judged the quality of evidence for these outcomes to be very low-moderate. We downgraded the 
quality of evidence by none to two levels for no, serious or very serious limitations to study quality 
due to risk of bias (arising from under-reporting, performance bias, detection bias and/or attrition 
bias), and one or two levels for imprecision (arising from low or very low participant numbers/event 
rates). 
 
See also the results section of the Supplementary File for tables of all the adverse events reported by 
the included studies along with the remaining forest plots of the pooled analyses reported in Table 1.  
 
quality of life 
The majority of the studies did not report quality of life;[12-13, 16-19, 22, 25-26, 28, 31-32, 34, 37-
39, 41-42] but Mucci-LoRusso et al reported no clinically significant changes in quality of life for 
either CR oxycodone or CR morphine group, but did not show results or analyses;[35] Gabrail et al 
observed no differences in quality of life (general activity, mood, walking ability, normal work, 
relationships with others, sleep, and enjoyment of life) between CR oxycodone to ER 
oxymorphone;[20-21] and Su et al found no differences in quality of life between CR oxycodone and 
TD fentanyl as measured by the Karnofsky Performance Status.[40] Moreover, treatment acceptability 
ratings were not significantly different between CR and IR oxycodone,[29-30, 33, 36] or CR 
oxycodone and CR morphine,[27, 35] although Heiskanen et al found that the mean daily 
acceptability of treatment ratings were significantly higher for CR morphine than for CR 
oxycodone.[23-24] 
We judged the quality of evidence for this outcome to be low-very low. We downgraded the quality 
of evidence by two levels for very serious limitations to study quality due to risk of bias (arising from 
under-reporting and attrition bias), and we downgraded none, one or two levels for imprecision 
(arising from low or very low participant numbers). 
 
patient preference 
Treatment preference did not differ significantly between CR oxycodone and CR morphine,[18-19] 
CR oxycodone and CR hydromorphone,[22] or between IV oxycodone followed by IR oxycodone 
and IV morphine followed by IR morphine.[25-26] Gabrail et al reported no data for participant 
preference, but found that 78.3% of participants rated oxycodone as 'excellent,' 'very good,' or 'good' 
with 86.4% of the participants giving oxymorphone such ratings.[20-21] 
 
We judged the quality of evidence for this outcome to be very low. We downgraded the quality of 
evidence by two levels for very serious limitations to study quality due to risk of bias (arising from 
under-reporting and attrition bias), and we downgraded the quality of the evidence by two levels due 
to imprecision (arising from very low participant numbers). 
 
Patient preference was not reported by the remaining studies.[12-13, 16-17, 23-24, 27-40] 
See also the µSummary of findings¶ tables in the results section of the Supplementary File. 
 
DISCUSSION   
There was no difference in pain intensity or adverse event rates after treatment with either CR or IR 
oxycodone.. Three of the four studies also found no difference in treatment acceptability between the 
comparisons. We noted that IR oxycodone was given every six hours rather than every four hours in 
these studies. This might have biased the efficacy data in favour of CR oxycodone; however, the 
adverse effect data suggest that giving IR oxycodone every four hours (more frequently) would have 
resulted in greater adverse effects, which would have mitigated advantages in efficacy. 
 
Nine studies compared CR oxycodone to CR morphine and pooled analysis of seven of these nine 
studies suggested that pain intensity did differ significantly between the treatments. However, this 
result was not corroborated by a sensitivity analysis that excluded the two cross-over trials included in 
the overall analysis. There were no marked differences in terms of treatment acceptability or quality 
of life ratings observed between the treatments. Zhang et al also found no significant differences in 
pain relief rates between CR oxycodone, CR morphine and CR MS Contin.[42] Pooled analyses of the 
adverse event rates also found no differences between the treatments for any of the adverse events, 
with the exception of hallucinations, which participants treated with CR morphine were at almost 
double the risk of experiencing compared to participants treated with CR oxycodone. However, these 
findings contrast somewhat with those reported by Lauretti et al,[27] which concluded that CR 
oxycodone combined with IR morphine is associated with superior analgesia and lower or similar 
rates of adverse events than a combination of CR and IR morphine.[27] 
 
Two studies compared CR oxycodone to TD fentanyl and pooled analysis of them found that the pain 
intensity scores after treatment with CR oxycodone and TD fentanyl did not differ significantly. One 
of the studies also found that quality of life did not differ between the treatments, but there was some 
disagreement between the study results in terms of adverse events with one of the studies finding that 
the rates of nausea and vomiting, and constipation were significantly higher in the CR oxycodone 
group than in the TD fentanyl group, whereas the other study reported no treatment group differences 
in (these and other) adverse event rates. 
 
The remaining studies all compared either oxycodone in different formulations or oxycodone to 
different alternative opioids and none of them found any clear superiority or inferiority of oxycodone 
for cancer pain, neither as an analgesic agent nor in terms of adverse event rates or treatment 
acceptability.  
 
Although the findings of this review are applicable to the population and comparisons defined for this 
review, that is, adults with cancer who need treatment with strong opioids for cancer pain, they should 
be taken in the context that this review found 23 studies that were eligible for inclusion and these 
studies reported on 13 different comparisons involving oxycodone and included only 2648 
participants. Moreover, for some of the outcomes (participant preference and quality of life) there 
were extremely few data available. To somewhat mitigate this shortfall, we reported treatment 
acceptability as a proxy. However, that does not change the fact that the evidence base for the 
effectiveness and tolerability of oxycodone (relative or absolute) for pain in adults with cancer was 
very limited and it did not allow us to examine the effectiveness and tolerability of oxycodone in 
detail through participant or treatment subgroup analyses. The current evidence base would therefore 
benefit from more well-designed, large RCTs. 
 
The quality of the evidence for all the outcomes was low or very low, meaning we have little 
confidence in the effect estimate and the true effect may be substantially different from the estimate of 
the effect. This is due to imprecision (low participant numbers) in some cases, and serious or very 
serious study limitations in all cases. In general, the assessment of the quality of the included studies 
was limited by a great extent of under-reporting in the studies, especially for the participant selection 
items (random sequence generation and allocation concealment), while blinding appeared to be 
reasonably well undertaken overall, both in terms of treatment performance and outcome assessment. 
However, as is not unusual for pain research, the results were substantially compromised by attrition, 
with data missing from just under 20% of the enrolled/randomised participants for efficacy, and from 
more than 10% for safety. These are substantial proportions and, while it did not appear to be 
selective attrition, the results must be interpreted with caution. 
 
Our conclusions are in agreement with those of other systematic reviews in this area despite some 
differences in inclusion criteria and analysis strategy.e.g.,[43-46] 
 
CONCLUSIONS   
 
Implications for practice 
We found low quality evidence that oxycodone offers similar levels of cancer pain relief and adverse 
events to other strong opioids including morphine, which is commonly considered the gold standard 
strong opioid. Although we identified a clinically insignificant benefit on pain relief in favour of CR 
morphine compared to CR oxycodone, this did not persist following sensitivity analysis and so we do 
not consider this important. We found an increased frequency of hallucinations after treatment with 
CR morphine (7.8%) compared to CR oxycodone (4%), but we also found a numerically higher 
frequency of myoclonus (another excitatory opioid adverse effect) with CR oxycodone and we did not 
find any differences in reported drowsiness or confusion. The interpretation of increased relative risk 
of hallucinations should therefore be treated with caution given the low quality of evidence. Our 
findings are consistent with current international guidance that oxycodone can be used first-line as an 
alternative to morphine. However, because it is cheaper, morphine generally remains the first-line 
opioid of choice for adults with cancer-related pain. 
 
Implications for research   
We found that the current evidence base is comprised of studies that contained small numbers of 
participants in which there was a significant (19%) dropout rate. For example, the direct comparison 
meta-analysis between oxycodone and morphine was based on fewer than 450 cancer participants in 
each treatment group; this was a very small evidence base. However, given the absence of important 
differences within this analysis, it seems unlikely that larger head to head studies of oxycodone versus 
morphine will be justified. For future cancer pain studies, developing a single outcome that combines 
good pain control (no more than mild on a verbal rating scale) with acceptable adverse effects 
(perhaps no more than mild severity on any adverse event) would enable a clearer comparison 
between any analgesics used in this context. 
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FIGURE LEGENDS  
Figure 1: Risk of bias summary: review authors' judgements about each risk of bias item for each 
included study. 
Figure 2: Mean (and standard deviation) pain intensity/relief scores after treatment with oxycodone or 
its comparator, sub-grouped by treatment comparisons (on the left side). Please note that pain 
intensity/relief was measured on different scales in some of the studies and are therefore not 
comparative between the studies. The meta-analysis therefore uses the standardised mean difference 
as the outcome measure (on the right side).   
Figure 3: Headache (adverse events) rates in patients receiving treatment with controlled-release (CR) 
and immediate-release (IR) oxycodone   
Figure 4: Sweating (adverse event) rates in patients receiving treatment with controlled-release (CR) 
and immediate-release (IR) oxycodone 
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morphine   
Figure 6: Constipation (adverse event) rates in patients receiving treatment with controlled-release 
(CR) and immediate-release (IR) oxycodone, CR oxycodone and CR morphine, and CR morphine and 
transdermal (TD) fentanyl, respectively. Please note, for the CR morphine and TD fentanyl 
comparison, the subtotal listed should be disregarded due to substantial heterogeneity (I2 = 83%); 
instead the included data should be considered on a study-by-study basis only.  
 
